SLDB analyst estimates
Solid Biosciences (SLDB) analyst ratings, the average price target and its range, and every firm's latest call.
SLDB analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 16, 2026 | RBC Capital | Solid Biosciences initiated with an Outperform at RBC Capital | $18.00 |
| Sep 14, 2026 | Loop Capital Markets | H.C. Wainwright Reiterates Buy Rating on Solid Biosciences (SLDB) | $25.00 |
| Aug 27, 2026 | Cantor Fitzgerald | Solid Biosciences price target raised to $26 from $16 at Cantor Fitzgerald | $26.00 |
| Aug 21, 2026 | Truist Financial | Solid Biosciences assumed with a Buy at Truist | $20.00 |
| May 13, 2026 | Piper Sandler | Solid Biosciences price target raised to $18 from $17 at Piper Sandler | $18.00 |
| May 13, 2026 | Wedbush | Solid Biosciences price target lowered to $16 from $17 at Wedbush | $16.00 |
| Dec 4, 2025 | Needham | Solid Biosciences initiated with a Buy at Needham | $16.00 |
| Nov 4, 2025 | Barclays | Solid Biosciences price target lowered to $9 from $10 at Barclays | $9.00 |
| Jul 21, 2025 | Cantor Fitzgerald | Cantor Fitzgerald Reiterates Overweight Rating on Solid Biosciences (SLDB) | $16.00 |
| Jun 24, 2024 | Leerink Partners | Leerink Partners Upgrades Solid Biosciences (SLDB) to Outperform | $12.00 |
| May 31, 2024 | Piper Sandler | Solid Biosciences transferred with Overweight rating at Piper Sandler | $20.00 |
| May 16, 2024 | Barclays | Solid Biosciences price target lowered to $18 from $21 at Barclays | $18.00 |
| Mar 13, 2024 | Raymond James | Piper Sandler Upgrades Solid Biosciences (SLDB) to Overweight, 'Still See Significant Upside Potential Despite Recent Move' | $20.00 |
- 8 firms rate SLDB: 8 buy, 0 hold, 0 sell.
- The average price target is $20.50 from None analysts, from $16.00 to $26.00.
Updated 2026-11-10 04:45 UTC